Quantification of cell-Associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2866-2870

  Podany, Anthony T ^a   Winchester, Lee C ^a   Robbins, Brian L ^a   Fletcher, Courtney V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CELL EXTRACT; DARUNAVIR; EFAVIRENZ; LOPINAVIR; RITONAVIR; BENZOXAZINE DERIVATIVE; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; SULFONAMIDE;

ARTICLE; CALIBRATION; CELL COUNT; CELL DENSITY; CELL LEVEL; CLINICAL PHARMACOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; LIQUID CHROMATOGRAPHY; METABOLISM; MONONUCLEAR CELL;

BENZOXAZINES; CELL EXTRACTS; CHROMATOGRAPHY, LIQUID; HUMANS; LEUKOCYTES, MONONUCLEAR; LOPINAVIR; MASS SPECTROMETRY; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SULFONAMIDES;

EID: 84898669966     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02551-13     Document Type: Article

References (21)

1. UNAIDS. 2012. Global report 2012: UNAIDS report on the global AIDS epidemic. http://www.unaids.org/en/resources/publications/2012/name, 76121,en.asp.
2. World Health Organization. 2013. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization, Geneva, Switzerland.
3. U.S. Department of Health and Human Services. 2013. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
4. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4 T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200:761-770. http://dx.doi.org/10.1084/jem. 20041196.
5. Mehandru S, Tenner-Racz K, Racz P, Markowitz M. 2005. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. J. Allergy Clin. Immunol. 116:419-422. http://dx.doi.org/10.1016/j.jaci.2005. 05.040.
6. Nagler-Anderson C. 2001. Man the barrier! strategic defences in the intestinal mucosa. Nat. Rev. Immunol. 1:59-67. http://dx.doi.org/10.1038/ 35095573.
7. Chun T-W, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI. 2008. Persistence of HIV in gut-Associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 197:714-720. http://dx.doi.org/10.1086/527324.
8. U.S. Department of Health and Human Services Food and Drug Administration. 2001. Guidance for industry, bioanalytical methods validation. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
9. Matuszewski B, Constanzer M, Chavez-Eng C. 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75:3019-3030. http://dx.doi.org/10.1021/ac020361s.
10. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, Fauci AS. 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 88:9838-9842. http://dx.doi.org/10.1073/pnas.88.21.9838.
11. Di Mascio M, Srinivasula S, Bhattacharjee A, Cheng L, Martiniova L, Herscovitch P, Lertora J, Kiesewetter D. 2009. Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob. Agents Chemother. 53:4086-4095. http://dx.doi.org/10.1128/AAC.00419-09.
12. Horiike M, Iwami S, Kodama M, Sato A, Watanabe Y, Yasui M, Ishida Y, Kobayashi T, Miura T, Igarashi T. 2012. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 423:107-118. http://dx.doi.org/10. 1016/j.virol.2011.11.024.
13. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA. 2010. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 84:2913-2922. http://dx.doi.org/10.1128/JVI.02356-09.
14. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. 27 January 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. U. S. A. http://dx.doi.org/10.1073/pnas.1318249111.
15. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237. http://dx.doi.org/10.1093/jac/dkm476.
16. D'Avolio A, Simiele M, Siccardi M, Baietto L, Sciandra M, Oddone V, Stefani FR, Agati S, Cusato J, Bonora S. 2011. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J. Pharm. Biomed. Anal. 54: 779-788. http://dx.doi.org/10.1016/j.jpba.2010.10.011.
17. Baheti G, Kiser JJ, Havens PL, Fletcher CV. 2011. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob. Agents Chemother. 55:5294-5299. http://dx.doi.org/10. 1128/AAC.05317-11.
18. Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. 2004. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:2388-2393. http://dx.doi.org/10.1128/AAC.48.7.2388-2393.2004.
19. Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, Lou Y, Yuen GJ, Min SS, Guerini EM. 2009. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 53:1532-1538.
20. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, Clavel F. 1999. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob. Agents Chemother. 43:2629-2634.
21. Piliero P, Shachoy-Clark A, Para M, Preston S, Lou I, Drusano G, Stein D, Yuen G. 2003. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK protocol CNA10905). Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., p 14-17.